Cancer combo trial halted early: what we know
NCT ID NCT05221320
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tested two drugs—ulixertinib and hydroxychloroquine—in 47 people with advanced gastrointestinal cancers that have certain genetic mutations (MAPK pathway). The goal was to see if the combination could shrink tumors. However, the study was terminated early, so the full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ulixertinib and hydroxychloroquine
- What this could lead to
- If successful, this combination could offer a new treatment option for advanced gastrointestinal cancers with specific genetic mutations.
- What could go wrong
- The trial was terminated early, so we have limited data on effectiveness. It was also a small, early-phase study, so results may not apply broadly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Massey Cancer Center, Virginia Commonwealth University
Richmond, Virginia, 23298, United States
-
Mount Sinai
New York, New York, 10029, United States
-
Rogel Cancer Center, University of Michigan Health
Ann Arbor, Michigan, 48109, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
University of Arizona Cancer Center
Tucson, Arizona, 85719, United States
-
University of California San Francisco
San Francisco, California, 94143, United States
-
University of Kansas Cancer Center
Fairway, Kansas, 66205, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can sound waves supercharge immunotherapy against bile duct cancer?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill rouse the immune system against pancreatic cancer?
- Can an immunotherapy combo shrink stomach tumors before surgery?